When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
DNLI - Denali's DNL310 nabs accelerated review status in U.S. for MPS II
Denali Therapeutics Inc.
The FDA grants Orphan Drug and Rare Pediatric Disease Designation status to Denali Therapeutics' (DNLI+0.6%) DNL310 for the treatment of mucopolysaccharidosis II (MPS II), also known as Hunter syndrome, a rare inherited disorder characterized by a large head, excess fluid in the brain and enlarged liver and spleen.
More news on: Denali Therapeutics Inc., Healthcare stocks news,